Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers

NCT04262466 is registered in ClinicalTrials.gov with Immunocore Ltd as lead sponsor.

NCT NCT04262466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04262466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Lead sponsor
Immunocore Ltd
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 25, 2020
Completion date
December 31, 2027
Enrollment
410 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

select advanced solid tumors